M
MyoKardia
Develops novel, small molecule therapeutics that address key clinical needs of patients with genetic heart diseases
At a glance
- Status
- Listed
- Listing
- IPO 2015
News
Open roles
MyoKardia in the San Francisco ecosystem
The MyoKardia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- CGCowen Group
Casdin Capital- SASanofi
BridgeBio
Cormorant Asset Management
Third Rock Ventures
Series B and later4 investors entered at this stage
- UBUniversity of Colorado Boulder
- SUStanford University
- HUHarvard University
- HSHarvard Medical School
Source: Dealroom Talent Intelligence.
Alumni founders
Former MyoKardia employees who went on to found companies, sorted by Dealroom signal score.
Jay EdelbergUnited States
BRBridgeBioEst. 2014
Neil KumarUnited States
June LeeUnited States
Priyanka Agarwal, MD, MBAUnited States
MTMaze TherapeuticsEst. 2018
Eric GreenUnited StatesPatents
31 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See MyoKardia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


